The first and only all-oral fixed-duration regimen in 1L CLL*

*Designed to be completed in fourteen 28-day cycles (2 cycles of CALQUENCE monotherapy followed by 12 cycles of CALQUENCE + venetoclax, starting venetoclax using a 5-week ramp-up as per dose schedule), unless disease progression or unacceptable toxicity warrants earlier discontinuation.

Dear Healthcare Professional,

CALQUENCE in combination with venetoclax is now FDA-approved for adult patients with previously untreated chronic lymphocytic leukemia.*

Have you seen efficacy and safety results from
the AMPLIFY Phase 3 trial in 1L CLL?

1L=first-line; CLL=chronic lymphocytic leukemia; FDA=Food and Drug Administration.

Indication and Usage

CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Select Safety Information

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are upper respiratory tract infection, diarrhea, headache, and musculoskeletal pain. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, uric acid increased, absolute lymphocyte count decreased, and platelets decreased.

Please see full Prescribing Information , including Patient Information .

You may report side effects related to AstraZeneca products  .

Click here to connect with an AstraZeneca sales representative.

Reference: CALQUENCE^® (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.